Deficiency of p53 and PTEN expression induces B7-H3 overexpression in cancer cells, and their study demonstrated that B7-H3 inhibitors, in combination with antibodies such as anti-CTLA4 and anti-PD-1, showed high efficacy in a p53/PTEN-deficient mouse model of prostate cancer. This evidence concerns the gene TP53 and prostate carcinoma.